Bristol-Myers Squibb Co (NYSE:BMY) announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to extend the current …
Friday morning before market open, Bristol-Myers Squibb Co (NYSE:BMY) came to terms with the failure of its Phase III CheckMate-026 trial evaluating Opdivo …
Bristol-Myers Squibb Co (NYSE:BMY) announced that CheckMate -026, a trial investigating the use of Opdivo(nivolumab) as monotherapy, did not meet its primary endpoint of …
On Monday, Uniqure NV (NASDAQ:QURE) and Bristol-Myers Squibb Co (NYSE:BMY) announced an exclusive strategic collaboration in which the agreement gives Bristol-Myers “exclusive …
